Successful treatment with low-dose imatinib mesylate of therapy-related myeloid neoplasm harboring TEL-PDGFRB in a patient with acute promyelocytic leukemia

Haematologica

Volumn 95, Issue 9, 2010, Pages

  Asou, Norio ^a   Iwanaga, Eisaku ^a   Nanri, Tomoko ^a   Mitsuya, Hiroaki ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Imatinib; Tel pdgfrb; Therapy related myeloid neoplasm

Indexed keywords

ACLARUBICIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; HEMOGLOBIN; HYBRID PROTEIN; IDARUBICIN; IMATINIB; MITOXANTRONE; RETINOIC ACID; TRANSCRIPTION FACTOR ETV6 PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR FUSION PROTEIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME TRANSLOCATION 12; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 5; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; GINGIVA BLEEDING; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPANESE; KARYOTYPING; LABORATORY TEST; LETTER; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROMYELOCYTIC LEUKEMIA; PROTEIN ANALYSIS; PURPURA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE COUNT; TREATMENT DURATION; TUMOR DIFFERENTIATION;

HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION;

EID: 77956828605     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.27656     Document Type: Letter

References (12)

1. Larson RA. Therapy-related myeloid neoplasms. Haematologica. 2009;94(4):454-459.
2. Latagliata R, Petti MC, Fenu S, Mancini M, Spiriti MA, Breccia M, et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood. 2002;99(3):822-824.
3. Lobe I, Rigal-Huguet F, Vekhoff A, Desablens B, Bordessoule D, Mounier C, et al. Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. Leukemia. 2003;17(8):1600-1604.
4. Asou N, Kishimoto Y, Kiyoi H, Okada M, Kawai Y, Tsuzuki M, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood. 2007;110(1):59-66.
5. Iwanaga E, Nanri T, Matsuno N, Kawakita T, Mitsuya H, Asou N. A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia. Haematologica. 2009;94 (3):433-435.
6. Ahmed F, Osman N, Lucas F, Neff G, Smolarek T, Bennett JM, et al. Therapy related CMML: a case report and review of the literature. Int J Hematol. 2009;89(5):699-703.
7. Oo TH, Kenney L. Therapy-related chronic myelomonocytic leukemia with unique chromosomal abnormalities: monosomy 7 and t(12;17)(p13;q11.2). Am J Hematol. 2007;82(3):248-249.
8. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002; 347(7):481-487.
9. David M, Cross NC, Burgstaller S, Chase A, Curtis C, Dang R, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood. 2007;109(1):61-64.
10. Intermesoli T, Delaini F, Acerboni S, Salmoiraghi S, Spinelli O, Guerini V, et al. A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes. Br J Haematol. 2009;147(5):681-685.
11. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7(2):129-141.
12. Shin J, Kim M, Kim DB, Yeom JO, Lee HJ, Cho SG. Sustained response to low-dose imatinib mesylate in a patient with chronic myelomonocytic leukemia with t(5;12)(q33;p13). Acta Haematol. 2008;119(1):57-59.